Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Sagimet Biosciences (SGMT) Return on Capital Employed (2023 - 2026)

Sagimet Biosciences' Return on Capital Employed history spans 4 years, with the latest figure at 45.62% for Q1 2026.

  • Quarterly Return on Capital Employed changed N/A to 45.62% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 45.62% through Mar 2026, changed N/A year-over-year, with the annual reading at 42.69% for FY2025, 121.0% up from the prior year.
  • Return on Capital Employed came in at 45.62% for Q1 2026, up from 48.48% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 32.64% in Q4 2023 to a low of 51.97% in Q3 2025.
  • The 4-year median for Return on Capital Employed is 48.48% (2025), against an average of 44.57%.
  • Year-over-year, Return on Capital Employed crashed -75bps in 2024 and then tumbled -1509bps in 2025.
  • Sagimet Biosciences' Return on Capital Employed stood at 32.64% in 2023, then dropped by -2bps to 33.39% in 2024, then crashed by -45bps to 48.48% in 2025, then increased by 6bps to 45.62% in 2026.
  • Per Business Quant, the three most recent readings for SGMT's Return on Capital Employed are 45.62% (Q1 2026), 48.48% (Q4 2025), and 51.97% (Q3 2025).